For Immediate Release
Media Contact: Kriss Bivens Cloyd
(208) 334-4119

Date: June 4, 2014

Idaho Reaches Settlement with GlaxoSmithKline

(Boise) – Pharmaceutical company GlaxoSmithKline, LLC (GSK) will pay the State more than $1.3 million as part of a $105 million multistate settlement, Attorney General Lawrence Wasden said. The settlement with GSK resolves allegations that the company unlawfully promoted its asthma drug, Advair®, as well as antidepressant drugs Paxil® and Wellbutrin®. Wasden joined 44 other states in the settlement. Wasden's lawsuit alleged the company violated the Idaho Consumer Protection Act by misrepresenting the uses and qualities of the drugs.

"Idahoans relied on the advertising claims made by this company and expected the company to tell the truth about the proper use and advantages of taking the drug," Attorney General Wasden said.

The Consent Judgment also requires GSK to reform its marketing and promotional practices. Specifically, GSK shall not:

  • Make, or cause to be made, any written or oral claim that is false, misleading, or deceptive about any GSK product;
  • Make promotional claims not approved or permitted by the FDA that a GSK product is better, more effective, safer, or has fewer serious side effects than has been demonstrated through substantial evidence or clinical experience;
  • Present data or conclusions from a clinical study that is inadequate in design, scope, or conduct;
  • Provide samples of GSK products to doctors who are not expected to prescribe the sampled GSK products for an approved use;
  • Disseminate information describing any off-label use of a GSK product, unless such information and materials are consistent with applicable FDA regulations and FDA Guidelines for Industry.

The Consent Judgment also requires GSK to continue its Patient First Program through March 2019. The Patient First Program reduces financial incentives for sales representatives to engage in deceptive marketing. In addition, the Judgment requires scientifically-trained personnel to be ultimately responsible for developing and approving responses to healthcare provider questions and for these responses to be unbiased and non-promotional.

Read the Complaint >>

Read the Consent Judgment >>

- End -

News by Year: